Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles

Published:2024-09 Issue:9 Volume:5 Page:100869
ISSN:2666-5247
Container-title:The Lancet Microbe
language:en
Short-container-title:The Lancet Microbe

Author:

Gillespie Stephen H^ORCID,DiNardo Andrew R,Georghiou Sophia B^ORCID,Sabiiti Wilber^ORCID,Kohli Mikashmi,Panzner Ursula,Kontsevaya Irina^ORCID,Hittel Norbert,Stuyver Lieven J^ORCID,Tan Jia Bin,van Crevel Reinout,Lange Christoph,Thuong Thuong Nguyen Thuy,Heyckendorf Jan,Ruhwald Morten,Heinrich Norbert

Funder

Loyola Marymount University

Innovative Medicines Initiative

Deutsches Zentrum für Infektionsforschung

Horizon 2020

IMI

University Hospitals

European Federation of Pharmaceutical Industries and Associations

Bundesministerium für Bildung und Forschung

German Federal Ministry of Health

Publisher

Elsevier BV

Reference42 articles.

1. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis;Gillespie;N Engl J Med,2014

2. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay;Sabiiti;Thorax,2020

3. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis;Conradie;N Engl J Med,2022

4. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis;Boeree;Am J Respir Crit Care Med,2015

5. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial;Diacon;Lancet,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP